-
公开(公告)号：US07803538B2
公开(公告)日：2010-09-28
申请号：US10869977
申请日：2004-06-17
申请人： Sandrine Mace , Sylvain Ricard , Emmanuelle Cousin , Laurent Pradier , Jésus Benavides , Jean-François Deleuze
发明人： Sandrine Mace , Sylvain Ricard , Emmanuelle Cousin , Laurent Pradier , Jésus Benavides , Jean-François Deleuze
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method for diagnosing an individual for early onset Alzheimer's disease by measuring the presence or absence of the minor allele of the rs908832 polymorphism of the ABCA2 gene. The presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene indicates that the individual may be suffering from Alzheimer's disease or exhibits an increased risk of developing Alzheimer's disease.
摘要翻译： 本发明涉及通过测定ABCA2基因的rs908832多态性的次要等位基因的存在或不存在来诊断个体的早发性阿尔茨海默病的方法。 ABCA2基因的rs908832多态性的次要等位基因的存在表明该个体可能患有阿尔茨海默氏病或表现出发展为阿尔茨海默氏病的风险增加。
-
公开(公告)号：US20050003417A1
公开(公告)日：2005-01-06
申请号：US10869977
申请日：2004-06-17
申请人： Sandrine Mace , Sylvain Ricard , Emmanuelle Cousin , Laurent Pradier , Jesus Benavides , Jean-Francois Deleuze
发明人： Sandrine Mace , Sylvain Ricard , Emmanuelle Cousin , Laurent Pradier , Jesus Benavides , Jean-Francois Deleuze
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： Methods for the diagnosis or for the prognosis of Alzheimer's disease in an individual. Said method comprises at least one step of detection of the presence or absence of the minor allele of the rs908832 polymorphism of the ABCA2 gene. The presence of the minor allele of the rs908832 polymorphism of the ABCA2 gene indicates that the individual may be suffering from Alzheimer's disease or else exhibits an increased risk of developing Alzheimer's disease.
摘要翻译： 用于个体诊断或预测阿尔茨海默病的方法。 所述方法包括检测ABCA2基因的rs908832多态性的次要等位基因的存在或不存在的至少一个步骤。 ABCA2基因的rs908832多态性的次要等位基因的存在表明个体可能患有阿尔茨海默病，或者表现出发展为阿尔茨海默病的风险增加。
-
3.发明申请SINGLE NUCLEOTIDE POLYMORPHISMS IN THE PROMOTER OF VEGFA GENE AND THEIR USE AS PREDICTIVE MARKERS FOR ANTI-VEGF TREATMENTS 审中-公开VEGFA基因启动子中的单核苷酸多态性及其作为抗VEGF治疗的预测标记物公开(公告)号：US20130330341A1
公开(公告)日：2013-12-12
申请号：US14000942
申请日：2012-02-22
申请人： Marielle Chiron Blondel , Emmanuelle Cousin , Jean-Francois Deleuze , Jennifer Dreymann , Sandrine Mace
发明人： Marielle Chiron Blondel , Emmanuelle Cousin , Jean-Francois Deleuze , Jennifer Dreymann , Sandrine Mace
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： The invention relates to the treatment and the diagnosis of a group of patients bearing specific alleles of single nucleotide polymorphisms in the promoter region of the VEGFA gene. These patients are more responsive to Aflibercept and more likely to be efficiently treated by anti-VEGF therapy.
摘要翻译： 本发明涉及在VEGFA基因的启动子区域中具有单核苷酸多态性特异性等位基因的一组患者的治疗和诊断。 这些患者对Aflibercept更敏感，更有可能通过抗VEGF治疗有效治疗。
-
公开(公告)号：US08084198B2
公开(公告)日：2011-12-27
申请号：US11913873
申请日：2006-05-03
申请人： Detlef Kozian , Matthias Herrmann , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Matthias Herrmann , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
CPC分类号： C12Q1/6883 , C12Q1/6897 , C12Q2600/156 , C12Q2600/158
摘要： The use of the single nucleotide polymorphism (SNP) at position −(97) of the GIP gene for the identification of a cardiovascular disease or of an increased risk for developing a cardiovascular disease in a biological sample taken from an individual to be examined.
摘要翻译： 在GIP基因的位置（97）处使用单核苷酸多态性（SNP）来鉴定从被检查个体获取的生物样品中的心血管疾病或发展心血管疾病的风险增加。
-
公开(公告)号：US20100062431A1
公开(公告)日：2010-03-11
申请号：US12300200
申请日：2007-05-09
申请人： Detlef Kozian , Matthias Herrmann , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Matthias Herrmann , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , G01N33/6893 , G01N2800/32
摘要： The use of the single nucleotide polymorphism (SNP) of the ADAMTS4 gene for the identification of cardiovascular and peripheral vascular disorders or of an increased risk for developing cardiovascular and peripheral vascular disorders in a biological sample taken from an individual to be examined; the use of ADAMTS4 for identifying substances active in preventing and/or treating cardiovascular and peripheral vascular disorders and methods for doing so.
摘要翻译： 使用ADAMTS4基因的单核苷酸多态性（SNP）来鉴定从被检查个体获取的生物样品中的心血管和外周血管疾病或发展为心血管和外周血管疾病的风险增加的单核苷酸多态性（SNP） 使用ADAMTS4鉴别预防和/或治疗心血管和外周血管疾病的物质及其方法。
-
6.发明授权Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism 失效通过确定TAFI-Ile347多态性来鉴定血栓形成障碍风险的方法公开(公告)号：US07560290B2
公开(公告)日：2009-07-14
申请号：US11184010
申请日：2004-04-01
申请人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , Y10S436/811
摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder, to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，选择患有血栓形成疾病风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法，以及 通过采用TAFI-Ile347多态性制备药物和诊断方法。
-
7.发明申请Method of Diagnosis of a Predisposition to Develop Thrombotic Disease and Its Uses 失效诊断血栓形成疾病倾向的方法及其应用公开(公告)号：US20080038722A1
公开(公告)日：2008-02-14
申请号：US10592692
申请日：2005-03-16
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention refers to a method of diagnosis of a predisposition to develop thrombotic disease, to test systems and their use for the diagnosis of a predisposition to develop thrombotic disease, to a P2X1 promoter variant and its use for screening for an anti-thrombotic agent, and to methods for identifying an individual that can be prophylactically or therapeutically treated with an anti-thrombotic agent, or for adapting a therapeutic or prophylactic dose of an anti-thrombotic agent.
摘要翻译： 本发明涉及诊断发生血栓形成疾病的倾向，测试系统及其用于诊断倾向于发展血栓形成性疾病的用途的方法，以诊断P 启动子变体及其用于筛选抗血栓形成剂的用途，以及用于鉴定可以用抗血栓形成剂预防性或治疗性治疗的个体的方法，或用于调整治疗或预防剂量的抗血栓形成剂 血栓形成剂。
-
公开(公告)号：US20070292859A1
公开(公告)日：2007-12-20
申请号：US11574839
申请日：2005-08-27
申请人： Detlef Kozian , Heinz Goegelein , Karl-Ernst Siegler , Martina Jacobs , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Heinz Goegelein , Karl-Ernst Siegler , Martina Jacobs , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The invention concerns methods of identifying an increase in risk for coronary heart disease in an individual, wherein the presence of another amino acid than Glutaminic Acid at position 23 and/or the presence of another amino acid than Valine at position 337 in the Kir6.2 protein is determined in a sample. Moreover, probes, primers, polypeptides or polynucleotides suitable for said methods are claimed.
摘要翻译： 本发明涉及鉴定个体中冠状动脉心脏病风险增加的方法，其中在Kir6.2中存在另一个氨基酸比谷氨酸在第23位和/或存在另外一个氨基酸比缬氨酸337位置存在 在样品中测定蛋白质。 此外，要求适用于所述方法的探针，引物，多肽或多核苷酸。
-
9.发明申请Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-IIe347 polymorphism 失效通过确定TAFI-IIe347多态性来鉴定血栓形成障碍风险的方法公开(公告)号：US20060040296A1
公开(公告)日：2006-02-23
申请号：US11184010
申请日：2004-04-01
申请人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
CPC分类号： G01N33/6893 , Y10S436/811
摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，包括但不限于心房颤动，中风，延迟性间歇性神经功能缺损（PRIND），短暂性缺血发作（TIA），动脉粥样硬化性脑血管病（CVD）和/或冠状动脉疾病 心脏病以及用于选择具有血栓形成障碍风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法以及用于制备药物的方法和诊断方法 采用TAFI-Ile347多态性。
-
10.发明授权Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof 失效EDG5多态性V286A与II型糖尿病和静脉血栓形成/肺栓塞的关系及其用途公开(公告)号：US07888020B2
公开(公告)日：2011-02-15
申请号：US11834998
申请日：2007-08-07
申请人： Detlef Kozian , Evi Kostenis , Karl-Ernst Siegler , Martina Jacobs , Sylvain Ricard , Sandrine Mace , Jean-Francois Deleuze
发明人： Detlef Kozian , Evi Kostenis , Karl-Ernst Siegler , Martina Jacobs , Sylvain Ricard , Sandrine Mace , Jean-Francois Deleuze
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject.
摘要翻译： 本发明涉及鉴定受试者中II型糖尿病，静脉血栓形成或肺栓塞风险增加的方法，其中286位从缬氨酸（Val）到丙氨酸（Ala）的氨基酸交换的存在 在取自受试者的生物样品中的EDG5蛋白中。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.029 秒)
